Skip to main content
UniHealth

Doctor search

Laurence Katznelson, MD

Endocrinology · Los Angeles

NPI 1013082643

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
4
1 carrier
Office
1

Offices

1 location · Cedars-Sinai Medical Center · 788 clinicians in this group

Looking this up.

Hospitals listed: Cedars-Sinai Medical Center. That is not proof they admit you there this week.

Plans that list them

4 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Katznelson’s office at (310) 423-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026

California Medical Board record

Licence G87279 · Current

Licensed to practise in California · since 2004 · expires 2027-12-31 · University of California, Los Angeles School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Cedars-Sinai Medical CenterLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 78% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Postoperative sepsis rate: 7.77 (6.11 to 9.44) · 6,132 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.2 to 14.7) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 134.15 (109.33 to 158.98) · 557 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.386, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.661, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.628, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.503, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.8 (3 to 4.8) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.8) · 2,580 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Cedars-Sinai Medical Center

Behind the star rating — Deaths: 7 better, 1 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Cedars-Sinai Medical Center
Postoperative sepsis rateComplications and deaths7.77 (6.11 to 9.44) · 6,132 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.2 to 14.7) · 1,174 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths134.15 (109.33 to 158.98) · 557 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.386BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.661BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.628BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.503BetterOct 2024 – Sep 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits3.8 (3 to 4.8) · 1,174 casesBetterJan 2024 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.8) · 2,580 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.66 (0.06 to 1.25) · 8,257 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.06 (0.92 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.7 · 223 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths5.9 · 191 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths8.3 · 409 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths5.5 · 1,544 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths9.5 · 1,742 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths11.6 · 549 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.3 · 9,504 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.14 (0 to 0.28) · 29,170 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.19 (0.05 to 0.32) · 31,661 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.1 (3.06 to 5.14) · 11,199 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.38 (0.47 to 2.29) · 6,024 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.05 (1.24 to 2.86) · 10,075 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.2 (5.76 to 10.65) · 6,012 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.91 (0.72 to 3.11) · 2,803 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.75 (0.47 to 1.03) · 27,865 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.1 · 472 casesNoneApr 2023 – Mar 2025
SSI - Abdominal HysterectomyInfections1.437No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.168No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.9 · 492 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19 · 1,750 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits8.9 · 498 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-5.8 · 1,908 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits27.7 · 1,850 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 1,572 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits4.7 · 449 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10 · 172 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.1 · 240 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.1 to 17.5) · 1,197 casesNo differentJan 2022 – Dec 2024

What patients said (1,081 patients answered, 20% of those asked)

Patient survey stars by topic at Cedars-Sinai Medical Center
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information3
Overall hospital rating4
Quietness2
Recommend hospital4
Share of patients giving the best answer at Cedars-Sinai Medical Center
Room was "always" clean68%
Nurses "always" communicated well77%
Doctors "always" communicated well77%
Staff "always" explained57%
Yes, staff "did" give patients this information85%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand73%
Doctors "always" listened carefully76%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night51%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects42%
Yes, staff "did" give patients information about possible symptoms87%

Original Medicare doctor bills

$3,525

Medicare paid this office $3,525 for 43 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)26$2,538$98
Return visit (30+ min)15$646$43

Who their Medicare patients are

43 Original Medicare patients in 2024. Average age 69 · Women 44% · Health risk score 1.20. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.

Conditions among them: High blood pressure 51% · Coronary heart disease 30%.

The office billed $23,606, Medicare allowed $6,309 and paid $3,525; for 45 services of 5 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20244345691.20$23,606$3,525
2023133172711.34$85,598$15,116
2022122171701.22$86,573$13,551
2021139203681.47$110,773$16,089
2020121171681.43$84,259$11,619
2019127176691.61$29,535$12,137
2018131193681.78$31,321$11,763
2017138215661.50$37,928$13,436
2016144283701.75$73,328$20,794
2015126225701.38$48,566$14,692
2014115206651.23$40,675$11,758
2013102207661.34$46,812$14,362

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Return visit (30+ min)109$10,649$79
New patient visit (45+ min)26$3,069$118

2022: 2 services

Original Medicare services billed in 2022
Return visit (30+ min)106$10,974$76
New patient visit (45+ min)13$1,368$105

2021: 2 services

Original Medicare services billed in 2021
Return visit (30+ min)113$11,885$79
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$1,328$66

2020: 3 services

Original Medicare services billed in 2020
Return visit (30+ min)95$7,614$64
New patient visit (45+ min)13$1,386$107
Return visit (30+ min)14$1,030$74

2019: 3 services

Original Medicare services billed in 2019
Return visit (30+ min)37$2,966$69
Short return visit (20+ min)62$2,508$39
New patient visit (45+ min)13$1,399$108

2018: 4 services

Original Medicare services billed in 2018
Short return visit (20+ min)71$3,474$41
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes11$1,779$81
Return visit (30+ min)17$1,272$64
Short return visit (20+ min)20$715$34

2017: 3 services

Original Medicare services billed in 2017
Short return visit (20+ min)71$3,332$39
Short return visit (20+ min)29$1,799$45
New patient visit (45+ min)11$1,099$100

2016: 8 services

Original Medicare services billed in 2016
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes16$4,528$89
Short return visit (20+ min)61$3,390$43
Initial hospital care with moderate level of medical decision making at least 75 minutes15$2,632$164
New patient visit (45+ min)19$1,730$91
New patient visit (45+ min)12$1,458$121
Hospital discharge day management, more than 30 minutes12$1,167$97
Return visit (30+ min)22$1,020$46
Short return visit (20+ min)17$889$44

2015: 4 services

Original Medicare services billed in 2015
Short return visit (20+ min)63$2,941$38
Return visit (30+ min)33$2,780$68
New patient visit (45+ min)23$2,657$116
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$1,745$65

2014: 4 services

Original Medicare services billed in 2014
Return visit (30+ min)53$3,077$50
Short return visit (20+ min)61$2,931$45
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$1,601$64
New patient visit (30+ min)23$1,418$62

2013: 2 services

Original Medicare services billed in 2013
Return visit (30+ min)70$6,054$65
New patient visit (30+ min)21$1,385$66

Medicaid work

$494 in 2022

Medicaid paid $494 for 16 billed services this clinician did in 2022, up to 16 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2022
Return visit (30+ min)16$494
Medicaid work by year
202216116$494
202012112$435
See the largest Medicaid services in earlier years

2020

Largest Medicaid services in 2020
Return visit (30+ min)12$435

Drugs they prescribed that Part D paid

$745

Pharmacies billed $745 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 38) in 2024. Too few prescriptions to compare fairly with other clinicians.

26 generic and 12 brand-name prescriptions · $745 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Hydrocortisone14$161$11
Levothyroxine12$67$6

Year by year

Part D prescribing by year
202438None0% (0)32%$745
202340210% (0)53%$897
202263200% (0)32%$11,079
202168210% (0)50%$1,923
202093270% (0)58%$25,434
201987280% (0)49%$12,016
201810235None47%$66,017
20178421NoneNone$22,460
20167527NoneNone$38,302
201512026None65%$51,230
2014130290% (0)64%$84,153
2013151340% (0)55%$91,712

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 1 drug

Part D drugs prescribed in 2023
Levothyroxine27$417$15

2022: 2 drugs

Part D drugs prescribed in 2022
Desmopressin Acetate13$1,788$138
Levothyroxine20$322$16

2021: 2 drugs

Part D drugs prescribed in 2021
Hydrocortisone21$621$30
Levothyroxine34$523$15

2020: 2 drugs

Part D drugs prescribed in 2020
Levothyroxine60$1,111$19
Hydrocortisone24$485$20

2019: 1 drug

Part D drugs prescribed in 2019
Levothyroxine44$957$22

2018: 2 drugs

Part D drugs prescribed in 2018
Hydrocortisone14$821$59
Levothyroxine30$727$24

2017: 2 drugs

Part D drugs prescribed in 2017
Hydrocortisone23$758$33
Levothyroxine25$543$22

2016: 1 drug

Part D drugs prescribed in 2016
Levothyroxine11$244$22

2015: 3 drugs

Part D drugs prescribed in 2015
Androgel30$22,155$739
Omnitrope11$5,038$458
Hydrocortisone13$1,323$102

2014: 5 drugs

Part D drugs prescribed in 2014
Norditropin Flexpro13$18,010$1,385
Humatrope26$17,892$688
Androgel16$9,053$566
Omnitrope11$4,503$409
Hydrocortisone18$552$31

2013: 6 drugs

Part D drugs prescribed in 2013
Somatuline Depot12$39,082$3,257
Norditropin Flexpro18$17,543$975
Humatrope19$12,540$660
Androgel15$9,446$630
Hydrocortisone25$845$34
Levothyroxine12$141$12

Money from drug and device companies

$4,836 in 2025

Industry payments by year
202544$4,765$4,836
202424$28,962$29,301
202327$13,481$14,636
202222$1,275$1,302
202168$21,590$21,590
202059$11,435$11,591
2019220$13,073$15,968

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Ascendis Pharma EndocrinologyNone$4,315
1 payment
  • Consulting · 2025-11-27 · $4,315
Alexion PharmaceuticalsNone$450
1 payment
  • Consulting · 2025-07-09 · $450
Corcept TherapeuticsKorlym$37
1 payment
  • Meals for Korlym · 2025-07-09 · $37
Chiesi USAMycapssa$34
1 payment
  • Meals for Mycapssa · 2025-07-12 · $34
See all 4 published payments
Every published payment
Ascendis Pharma EndocrinologyConsulting · 2025-11-27None$4,315
Chiesi USAMeals · 2025-07-12Mycapssa$34
Alexion PharmaceuticalsConsulting · 2025-07-09None$450
Corcept TherapeuticsMeals · 2025-07-09Korlym$37
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $29,301

Payments by company in 2024
Corcept TherapeuticsKorlym$26,162
2 payments
  • Paid to speak or teach for Korlym · 2024-10-01 · $22,500
  • Consulting for Korlym · 2024-03-27 · $3,662
Alexion PharmaceuticalsNone$3,139
2 payments
  • Travel · 2024-07-16 · $339
  • Consulting · 2024-07-16 · $2,800

2023: $14,636

Payments by company in 2023
Novo NordiskNorditropin$9,124
6 payments
  • Travel · 2023-10-19 · $295
  • Meals · 2023-10-19 · $357
  • Travel · 2023-10-19 · $503
  • Consulting · 2023-10-19 · $5,906
  • Consulting · 2023-10-18 · $1,500
  • Consulting for Norditropin · 2023-01-26 · $563
Corcept TherapeuticsKorlym$5,513
1 payment
  • Consulting for Korlym · 2023-03-22 · $5,513

2022: $1,302

Payments by company in 2022
Corcept TherapeuticsKorlym$1,275
1 payment
  • Consulting for Korlym · 2022-09-28 · $1,275
Novo NordiskNone$27
1 payment
  • Meals · 2022-06-11 · $27

2021: $21,590

Payments by company in 2021
Recordati Rare Diseases Inc.None$5,875
2 payments
  • Honoraria · 2021-06-18 · $1,375
  • Honoraria · 2021-04-20 · $4,500
Xeris PharmaceuticalsNone$4,900
1 payment
  • Paid to speak or teach · 2021-03-15 · $4,900
Ipsen BiopharmaceuticalsSomatuline Depot$3,440
2 payments
  • Consulting for Somatuline Depot · 2021-12-15 · $1,720
  • Consulting for Somatuline Depot · 2021-01-05 · $1,720
Ipsen InnovationNone$3,010
1 payment
  • Consulting · 2021-06-15 · $3,010
Ipsen BiopharmSomatuline Depot$2,365
1 payment
  • Consulting for Somatuline Depot · 2021-01-15 · $2,365
Hra Pharma Rare DiseasesMetopirone$2,000
1 payment
  • Consulting for Metopirone · 2021-06-15 · $2,000

2020: $11,591

Payments by company in 2020
Corcept TherapeuticsKorlym$3,515
2 payments
  • Paid to speak or teach for Korlym · 2020-04-23 · $875
  • Consulting for Korlym · 2020-03-05 · $2,640
Recordati Rare Diseases Inc.None$3,025
1 payment
  • Honoraria · 2020-11-20 · $3,025
Novo NordiskNorditropin$2,876
4 payments
  • Consulting for Norditropin · 2020-11-24 · $1,360
  • Consulting for Norditropin · 2020-11-24 · $1,360
  • Meals for Norditropin · 2020-01-02 · $50
  • Travel for Norditropin · 2020-01-02 · $106
Strongbridge USNone$1,800
1 payment
  • Honoraria · 2020-12-10 · $1,800
MallinckrodtNone$375
1 payment
  • Consulting · 2020-06-09 · $375

2019: $15,968

Payments by company in 2019
Novo NordiskNorditropin$15,849
17 payments
  • Meals for Norditropin · 2019-12-06 · $50
  • Travel for Norditropin · 2019-12-06 · $256
  • Travel for Norditropin · 2019-12-06 · $361
  • Travel for Norditropin · 2019-12-06 · $556
  • Consulting for Norditropin · 2019-12-06 · $5,372
  • Travel for Norditropin · 2019-12-06 · $150
  • Travel for Norditropin · 2019-12-06 · $28
  • Meals for Norditropin · 2019-12-05 · $50
  • Consulting for Norditropin · 2019-12-05 · $2,346
  • Travel for Norditropin · 2019-12-05 · $28
  • Meals for Norditropin · 2019-05-03 · $12
  • Travel for Norditropin · 2019-05-03 · $196
  • Travel for Norditropin · 2019-05-03 · $221
  • Travel for Norditropin · 2019-05-03 · $762
  • Meals for Norditropin · 2019-05-03 · $19
  • Consulting for Norditropin · 2019-05-03 · $5,355
  • Travel for Norditropin · 2019-05-03 · $88
Corcept TherapeuticsKorlym$119
3 payments
  • Travel for Korlym · 2019-01-10 · $72
  • Travel for Korlym · 2019-01-10 · $27
  • Meals for Korlym · 2019-01-10 · $20

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Ascendis Pharma Inc · Foresight · 2023Their institution$55,782
Ascendis Pharma, Inc. · Foresight · 2022Their institution$19,294
Novartis Pharmaceuticals Corporation · An Open Label Multicenter Single Arm Study of Pasireotide Lar in Patients With Rare Tumors of Neuroendocrine Origin · 2019Their institution$6,403
Novartis Pharmaceuticals Corporation · An Open Label Multi Center Pasireotide Rollover Protocol for Patients Who Have Completed A Previous Novartis Sponsored Pasireotide Study and Are Judged By the Investigator To Benefit From Continued Pasireotide Treatment · 2019Their institution$3,954
Ascendis Pharma Inc · Foresight · 2024Their institution$3,520

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1013082643
Licence
CA G87279California G87279: Current · expires 2027-12-31
Trained
University of California, Geffen School of Medicine, 1985
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
Mailing address
4140 W 190th St, Torrance, CA, 90504
NPI first listed
2006-11-21
NPI last updated
2024-05-07
NPI record certified
2024-05-07

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305 · 875 Blake Wilbur Dr, Stanford, CA, 94035